Trials / Completed
CompletedNCT01603277
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Humanigen, Inc. · Industry
- Sex
- All
- Age
- 16 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Anti-GM-CSF Monoclonal Antibody 400mg | Anti-GM-CSF Monoclonal Antibody 400mg |
| OTHER | Placebo | Normal Saline |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-07-01
- Completion
- 2014-01-01
- First posted
- 2012-05-22
- Last updated
- 2015-02-02
- Results posted
- 2015-02-02
Locations
70 sites across 6 countries: United States, Australia, France, Poland, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT01603277. Inclusion in this directory is not an endorsement.